MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Oramed Pharmaceuticals ROE Ratio 2011-2026 | ORMP
Annual ROE Ratio Oramed Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.37 | -24.08 | -7.36 | -35.01 | -74.02 | -40.91 | -54.48 | -41.86 | -29.13 | -27.39 | -52.05 | -88.52 | -41.92 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.37 | -88.52 | -39.49 |
Quarterly ROE Ratio Oramed Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.36 | -22.06 | -25.43 | -6.46 | -8.63 | 1.81 | -4.21 | -5.23 | -9.84 | -12.27 | -18.36 | -18.09 | -25.46 | -26.97 | -24.39 | -22.55 | -41.15 | -60.93 | -63.56 | -78.55 | -67.41 | 20.76 | 51.43 | 56.36 | 56.27 | -37.5 | -75.22 | -75.31 | -71.53 | -80.49 | -76.71 | -72.94 | -72.8 | -8.65 | 9.19 | 10.26 | 10.64 | -33.65 | -47.65 | -47.21 | -44.61 | -4.44 | 10.72 | 11.23 | 3.85 | -58.03 | -118.87 | -123.58 | -123.53 | -169.74 | -206.22 | -217.77 | -216.85 | -170.26 | -123.66 | -111.13 | -41.94 | -41.92 | -12.85 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 56.36 | -217.77 | -46.94 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 3.56 | 2.01 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 0.79 | -0.79 % | $ 4.31 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-115.61 | - | 10.36 % | $ 9.8 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 231.03 | 2.23 % | $ 5 B |  Danmark |
 |
ADC Therapeutics SA
ADCT
|
-138.5 | $ 4.22 | 2.18 % | $ 105 M |  Schweiz |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.61 | 0.28 % | $ 8.69 B |  Australia |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-30.74 | $ 6.63 | -0.75 % | $ 182 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
-531.22 | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-38.95 | $ 14.36 | 1.13 % | $ 210 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 90.54 | -0.71 % | $ 27.2 B | Germany |
 |
Aptose Biosciences
APTO
|
559.76 | - | -45.71 % | $ 1.2 M | Canada |
 |
Burford Capital Limited
BUR
|
10.1 | $ 8.05 | 1.64 % | $ 1.31 B | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-116.29 | - | - | $ 521 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-57.49 | $ 6.05 | -0.82 % | $ 493 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.64 | 3.94 % | $ 16.6 M | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
BioCardia
BCDA
|
721.83 | $ 1.27 | 0.79 % | $ 26.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.51 | 4.86 % | $ 385 M | Britain |
 |
Athira Pharma
ATHA
|
-216.19 | - | - | $ 269 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-144.96 | $ 3.58 | -0.56 % | $ 7.79 B | Israel |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
AstraZeneca PLC
AZN
|
20.44 | - | - | $ 96.9 B | Britain |
 |
Actinium Pharmaceuticals
ATNM
|
-116.74 | $ 1.11 | - | $ 33.4 M | USA |